Thymosin beta 15A (TMSB15A) is a predictor of chemotherapy response in triple-negative breast cancer

por Darb-Esfahani, S, Kronenwett, R, von Minckwitz, G, Denkert, C, Gehrmann, M, Rody, A, Budczies, J, Brase, J C, Mehta, M K, Bojar, H, Ataseven, B, Karn, T, Weiss, E, Zahm, D M, Khandan, F, Dietel, M, Loibl, S
Publicado 2012

EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer

por Dubsky, P., Filipits, M., Jakesz, R., Rudas, M., Singer, C. F., Greil, R., Dietze, O., Luisser, I., Klug, E., Sedivy, R., Bachner, M., Mayr, D., Schmidt, M., Gehrmann, M. C., Petry, C., Weber, K. E., Kronenwett, R., Brase, J. C., Gnant, M.
Publicado 2013

The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2− breast cancer patients

por Dubsky, P, Brase, J C, Jakesz, R, Rudas, M, Singer, C F, Greil, R, Dietze, O, Luisser, I, Klug, E, Sedivy, R, Bachner, M, Mayr, D, Schmidt, M, Gehrmann, M C, Petry, C, Weber, K E, Fisch, K, Kronenwett, R, Gnant, M, Filipits, M
Publicado 2013